Skip to main content

CordenPharma changes hands

Private equity firm Atorg has agreed to acquire CDMO CordenPharma from International Chemical Investors Group (ICIG), subject to customary regulatory approvals. The founders, Patrick Schnitzer and Dr Achim Riemann, will also reinvest in the firm and CEO Michael Quirmbach remains in place.

Onyx Scientific opens second site

CDMO Onyx Scientific has opened a second facility at its headquarters site in Sunderland, UK.This doubles its footprint and allows for expansion of all CMC activities, including additional GMP facilities that increases capacity for GMP and commercial API manufacturing capacity by 50%.

Dow to add alkoxylation capacity

Dow has announced plans to expand its alkoxylation capacity in the US and Europe in 2024 and 2025. The investments are backed by supply agreements with customers and are being made to meet 10-15%/year growth in end markets including home and personal care, industrial and institutional cleaning, pharmaceuticals and crop protection.

Bachem in oligonucleotide deal

Bachem has entered a strategic collaboration under which it will provide the infrastructure and expertise to implement Eli Lilly & Company’s novel manufacturing technology for oligonucleotide APIs. It will also supply R&D and production at its site in Bubendorf, Switzerland, to make GMP-grade material using this technology.

Sumitomo Chemical to build API plant

Sumitomo Chemical has announced plans to build a new plant for APIs and intermediates to come onstream in September 2024 at its Oita works on the southern tip of Honshu. This comes in response to growing demand from the small molecule sector. No financial details were given.

Oita, the company said, “can manufacture a wide variety of APIs and intermediates that require complex chemical reactions and also flexibly scale from development to commercialisation”. It is also compliant with EU, US and Japanese GMP standards.

Japanese firms form API JV

Seven Japanese firms have come together to create a joint venture that will develop technology for continuous manufacturing (CM) of APIs and intermediates and a CDMO business using it. Pharmira, whose name comes from ‘pharmaceutical’ and the Japanese word for ‘future’, employs 27 and is based at Amagasaki.

PharmaZell-Novasep merger complete

Following negotiations begun in September 2021, PharmaZell, a German-based supplier of speciality APIs, and Novasep, a CDMO focused on complex small molecules and ADCs, have closed their merger under the majority ownership of Bridgepoint Group. Former PharmaZell CEO Dr Sylke Hassel (pictured) will be CEO, while former Novasep CEO Michel Spagnol has joined the board of directors.

Subscribe to Pharmaceuticals